HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nelson, D. Articles by Robinson, B. Search for Related Content PubMed PubMed Citation Articles by Nelson, D. Articles by Robinson, B.

In Vivo Cross-Presentation of a Soluble Protein Antigen: Kinetics, Distribution, and Generation of Effector CTL Recognizing Dominant and Subdominant Epitopes¹

Delia Nelson^2,*,, Christine Bundell^* and Bruce Robinson^*,

^* Department of Medicine, University of Western Australia, Nedlands, Australia; and West Australian Institute for Medical Research, Queen Elizabeth II Medical Center, Perth, Australia

Cross-presentation of exogenous Ags via the MHC class I pathway is now recognized for its role in self-tolerance, tumor immunity, and vaccine development. However, little is known about the in vivo distribution and kinetics of cross-presented protein Ags, nor the subsequent development of CTL effector responses to dominant or subdominant epitopes. We examined the location and duration of cross-presented Ag by using 5,6-carboxy-succinimidyl-fluorescein ester-labeled T cells from class I-restricted Ag-specific TCR mice. Comparisons of results from an in vitro ⁵¹Cr release CTL assay with an in vivo CTL assay provided physiologically relevant insights into the functional capacities of CTL specific for epitopes with differing affinities. These data demonstrate that efficient cross-presentation of a dominant class I-restricted Ag is dose related and remains largely localized, but not limited to the draining lymph nodes for up to 3 wk following a single injection of soluble protein. Within this period, dominant peptide-specific CTL are fully functional in vivo throughout the secondary lymphoid system. However, no in vivo responses are seen to a subdominant or cryptic epitope. Prolonging Ag cross-presentation via use of IFA promoted persisting in vivo dominant epitope-specific CTL activity and revealed dose-responsive precursor CTL to the subdominant, but not to a cryptic epitope. Analysis of functional in vivo CTL responses demonstrated that, in the presence of strong ongoing responses to the dominant peptide, lytic activity of CTL directed at weaker epitopes is undetectable.

This article has been cited by other articles:

				A. Takeuchi, Y. Itoh, A. Takumi, C. Ishihara, N. Arase, T. Yokosuka, H. Koseki, S. Yamasaki, Y. Takai, J. Miyoshi, et al. CRTAM Confers Late-Stage Activation of CD8+ T Cells to Regulate Retention within Lymph Node J. Immunol., October 1, 2009; 183(7): 4220 - 4228. [Abstract] [Full Text] [PDF]

				B. Garulli, M. G. Stillitano, V. Barnaba, and M. R. Castrucci Primary CD8+ T-Cell Response to Soluble Ovalbumin Is Improved by Chloroquine Treatment In Vivo Clin. Vaccine Immunol., October 1, 2008; 15(10): 1497 - 1504. [Abstract] [Full Text] [PDF]

				M. S. Bennett, H. L. Ng, M. Dagarag, A. Ali, and O. O. Yang Epitope-Dependent Avidity Thresholds for Cytotoxic T-Lymphocyte Clearance of Virus-Infected Cells J. Virol., May 15, 2007; 81(10): 4973 - 4980. [Abstract] [Full Text] [PDF]

				Y. Gao, J. Tao, M. O. Li, D. Zhang, H. Chi, O. Henegariu, S. M. Kaech, R. J. Davis, R. A. Flavell, and Z. Yin JNK1 Is Essential for CD8+ T Cell-Mediated Tumor Immune Surveillance J. Immunol., November 1, 2005; 175(9): 5783 - 5789. [Abstract] [Full Text] [PDF]

				P. Otahal, S. C. Hutchinson, L. M. Mylin, M. J. Tevethia, S. S. Tevethia, and T. D. Schell Inefficient Cross-Presentation Limits the CD8+ T Cell Response to a Subdominant Tumor Antigen Epitope J. Immunol., July 15, 2005; 175(2): 700 - 712. [Abstract] [Full Text] [PDF]

				A. B. Kamath, J. Woodworth, X. Xiong, C. Taylor, Y. Weng, and S. M. Behar Cytolytic CD8+ T Cells Recognizing CFP10 Are Recruited to the Lung after Mycobacterium tuberculosis Infection J. Exp. Med., December 6, 2004; 200(11): 1479 - 1489. [Abstract] [Full Text] [PDF]

				H. Fujiwara, F. El Ouriaghli, M. Grube, D. A. Price, K. Rezvani, E. Gostick, G. Sconocchia, J. Melenhorst, N. Hensel, D. C. Douek, et al. Identification and in vitro expansion of CD4+ and CD8+ T cells specific for human neutrophil elastase Blood, April 15, 2004; 103(8): 3076 - 3083. [Abstract] [Full Text] [PDF]

				J. R. Fulton, J. Smith, C. Cunningham, and C. F. Cuff Influence of the Route of Infection on Development of T-Cell Receptor {beta}-Chain Repertoires of Reovirus-Specific Cytotoxic T Lymphocytes J. Virol., February 1, 2004; 78(3): 1582 - 1590. [Abstract] [Full Text] [PDF]

				B. M. Sullivan, A. Juedes, S. J. Szabo, M. von Herrath, and L. H. Glimcher Antigen-driven effector CD8 T cell function regulated by T-bet PNAS, December 23, 2003; 100(26): 15818 - 15823. [Abstract] [Full Text] [PDF]

				J. de Jersey, D. Carmignac, T. Barthlott, I. Robinson, and B. Stockinger Activation of CD8 T Cells by Antigen Expressed in the Pituitary Gland J. Immunol., December 15, 2002; 169(12): 6753 - 6759. [Abstract] [Full Text] [PDF]

				S. Koido, Y. Tanaka, D. Chen, D. Kufe, and J. Gong The Kinetics of In Vivo Priming of CD4 and CD8 T Cells by Dendritic/Tumor Fusion Cells in MUC1-Transgenic Mice J. Immunol., March 1, 2002; 168(5): 2111 - 2117. [Abstract] [Full Text] [PDF]

				W. Lu, A. Achour, M. Arlie, L. Cao, and J.-M. Andrieu Enhanced Dendritic Cell-Driven Proliferation and Anti-HIV Activity of CD8+ T Cells by a New Phenothiazine Derivative, Aminoperazine J. Immunol., September 1, 2001; 167(5): 2929 - 2935. [Abstract] [Full Text] [PDF]

				D. J. Nelson, S. Mukherjee, C. Bundell, S. Fisher, D. van Hagen, and B. Robinson Tumor Progression Despite Efficient Tumor Antigen Cross-Presentation and Effective "Arming" of Tumor Antigen-Specific CTL J. Immunol., May 1, 2001; 166(9): 5557 - 5566. [Abstract] [Full Text] [PDF]